Gi Dynamics, Inc.

Conformal Medical, Inc.

Focal, Inc.

The University of Texas System

Incept, LLC

Other

Genzyme Corporation

David A Melanson

Andy H Levine

John C Meade

John F Cvinar

Ronald B Lamport

Aaron V Kaplan

Carol A Devellian

James H Loper

Michael T Radford

Barry Maxwell

Amarpreet S Sawhney

Andres Chamorro, Iii

Richard A Gambale

John C Spiridigliozzi

Jeffrey Alan Hubbell

Luis Z Avila

Arthur J Coury

Shikha P Barman

Andres Chamorro

Peter J Shank

George E Selecman

Stephen D Goodrich

Ronald S Rudowsky

Mark T Kieras

Dean M Pichon

Ian K Parker

David J Nedder

Chandrashekar P Pathak

Thomas S Bromander

Stuart A Randle

Farhad Khosravi

Stephen Jack Herman

Patrick K Campbell

Laurence A Roth

Bradley C Poff

Douglas J Weaver

Donald L Elbert

Michael G Dumont

John Panek

Christopher Nutting

Marc A Levine

Marc Alan Levine

Thomas Bromander

Peter G Edelman

Donald Leo Elbert

Michelle D Lyman

Jeffrey A Hubbell

Douglas J K Weaver

Sean K Holmes

Manoel Dos Passos Galvao Neto

Ezra S Fishman

Douglas JK Weaver

Devices and methods are described for occluding the left atrial appendage (LAA) to exclude the LAA from blood flow to prevent blood from clotting within the LAA and subsequently embolizing, particularly in patients with atrial fibrillation. An implant is delivered via transcatheter delivery into the LAA. The implant includes a conformable structure comprising a foam body and internal support. The support includes anchors that penetrate the foam body and anchor the implant to the walls of the LAA. The implant provides compliance such that it conforms to the native configuration of the LAA.

Devices and methods for excluding the left atrial appendage

Systems, devices and methods for occluding the left atrial appendage (LAA). The device excludes the LAA from blood flow. The implantable device is delivered via transcatheter delivery into the LAA and secured within the LAA. The implant comprises an expandable and compliant frame and an expandable and conformable tubular foam body. A delivery and tether retraction system includes a handle for controlling a pusher and tether. The pusher may be moved a distance away from the implant without changing the orientation of the implant, while the tether is still attached to the implant. Severing the tether and proximally retracting a control on the hand piece by a distance causes the severed end to advance distally by at least about twice that distance. A loader includes a conical portion with guides and a reservoir for submerging the foam prior to loading and delivery.

Devices and methods are described for occluding the left atrial appendage (LAA). The device excludes the LAA from blood flow to prevent blood from clotting within the LAA and subsequently embolizing, particularly in patients with atrial fibrillation. The implantable device is delivered via transcatheter delivery into the LAA and secured within the LAA. The implant comprises an expandable and compliant frame and an expandable and conformable tubular foam body carried by the frame. The device may have a thromboresistant cover at a proximal end and a thromboresistant coating on the foam body. The frame may have recapture struts inclining radially outwardly in the distal direction from a central hub. The frame may have axially extending side wall struts, with adjacent pairs of side wall struts joined at one or more apexes. Anchors extend from the frame to engage tissue. The anchors can also be reversible to allow retraction of the anchors and repositioning or retrieval of the device.

Devices and methods are described for occluding the left atrial appendage (LAA). The device excludes the LAA from blood flow to prevent blood from clotting within the LAA and subsequently embolizing, particularly in patients with atrial fibrillation. The implantable device is delivered via transcatheter delivery into the LAA and secured within the LAA. The implant comprises an expandable and compliant frame and an expandable and conformable tubular foam body. The device may have a thromboresistant cover at a proximal end. The frame may have recapture struts inclining radially outwardly from a central hub. The frame may have axially extending side wall struts, with adjacent pairs of side wall struts joined at one or more apexes. Anchors extend from the frame and into the foam to engage tissue.

Systems, devices and methods for occluding the left atrial appendage (LAA). The device excludes the LAA from blood flow. The implantable device is delivered via transcatheter delivery into the LAA and secured within the LAA. The implant comprises an expandable and compliant frame having anchors and an expandable and conformable tubular foam body. A delivery and tether retraction system includes a handle for controlling a pusher and tether. The pusher may be moved a distance away from the implant without changing the orientation of the implant, while the tether is still attached to the implant. A loader includes a conical portion with guides and a reservoir for submerging the foam implant prior to loading and delivery.

Devices and methods for occluding the left atrial appendage (LAA) to prevent blood from clotting within the LAA and subsequently embolizing, particularly in patients with atrial fibrillation. A foam implant encapsulated with a tough thromboresistent membrane is placed via transvascular means into the LAA and anchored with adhesives and/or mechanical anchors. Tissue over- and in-growth are optimized to anchor the implant in place and provide a permanent occlusion.

A gastrointestinal implant device () comprises a planar proximal element () configured to reside in a stomach to resist distal migration, a distal element () configured to reside in an intestine to resist proximal migration and one or more tethers () coupling the planar proximal element to the distal element.

Transpyloric anchoring

Devices and methods are described for occluding the left atrial appendage (LAA) to exclude the LAA from blood flow to prevent blood from clotting within the LAA and subsequently embolizing, particularly in patients with atrial fibrillation. A foam implant is delivered via transcatheter delivery into the LAA and anchored using an internal locking system of the implant. The locking system includes deployable anchors that can be deployed after deployment of the foam implant from the delivery catheter and expansion of the foam within the LAA. The implant location can thus be verified before deploying the anchors to secure the implant. The locking system can be reversible to allow retraction of the anchors and repositioning or retrieval of the implant.

Growing community of inventors

Hudson, NH, United States of America

David A Melanson